Aprea Therapeutics is a Boston, Massachusetts- and Stockholm, Sweden-based biopharmaceutical company focused on the discovery and development of novel anticancer compounds that reactivate the tumor suppressor protein, p53. The Company's lead drug candidate is APR-246, a first-in-class small molecule in clinical development for myelodysplastic syndromes (MDS) and high-grade serious ovarian cancer, and trials in additional hematologic malignancies are planned. Aprea is also developing second generation p53 reactivators that have best-in-class potential.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
11/30/18	$56,600,000		5AM Ventures HealthCap Karolinska Development Redmile Group Rock Springs Capital Sectoral Asset Management Versant Ventures	undisclosed